Loss to Follow-up in PDR Patients

Causes and Clinical Impact of Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04018326

Enrollment

467

Registered

2019-07-12

Start date

2013-05-01

Completion date

2018-12-25

Last updated

2019-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Keywords

loss to follow-up, proliferative diabetic retinopathy, diabetic retinopathy, panretinal photocoagulation, intravitreal injections

Brief summary

This study determined the clinical impact and causes of loss to follow-up (LTFU) from the patients' perspective in individuals with proliferative diabetic retinopathy (PDR) who received panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of anti-vascular endothelial growth factor (VEGF). This prospective cohort study included 467 patients with PDR who received PRP and/or IVIs of anti-VEGF between May 2013 and June 2018. LTFU was defined as missing any follow-up visit for any interval exceeding 6 months, provided that patients eventually resumed care. Main outcome measures include rates and causes of LTFU.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 70 Years

Inclusion criteria

* included treatment-naïve patients who had developed PDR in one eye with a best corrected visual acuity (BCVA) ranging from 20/22 to 20/69, as determined by the Snellen equivalent. Patients were allocated to receive PRP, IVIs of anti-VEGF, or a combination of both procedures.

Exclusion criteria

1. patients receiving follow-up ophthalmic care for their PDR with or without interventions at any other medical care provider during the observation period, as declared by the patients at any follow up visit. 2. patients LTFU who did not resume follow-up until the end of the observation period. 3. patients needing PPV at first presentation or having additional retinal pathology. 4) patients receiving their treatment procedure during December 2017 or having vitreous hemorrhage that failed to clear up by June 2018 but still ineligible candidates for PPV.

Design outcomes

Primary

Measure	Time frame	Description
Final BCVA	through study completion, an average of 1 year,	logMAR BCVA at final follow up (Snellen equivalent)
Final UCVA	through study completion, an average of 1 year,	Final logMAR UCVA (Snellen equivalent)

Outcome results